Source: Reuters

Xolair: Roche's Xolair reduces reactions to severe food allergies in study

Xolair, a 20-year-old asthma drug sold by Roche (ROG.S), opens new tab and Novartis (NOVN.S), opens new tab, significantly reduced allergic reactions in people with multiple severe food allergies in a late-stage trial, researchers reported on Sunday at a medical meeting.

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
100-250
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100

Read more